Biotech Startups

Verdesian Life Sciences is a leading agrochemical platform focused on biological and nutritional fertilizer enhancers, seed treatments, and inoculants for specialty crops. The company serves farmers and the agricultural industry.

2 investors

Verdiva Bio is a biotechnology company focused on drug development. Its leadership brings experience in in-licensing, commercialization, and business development across the international biotech industry.

2 investors

Vergent develops tumor-targeted fluorescent imaging agents designed to enhance surgeons' ability to visualize tumors during minimally invasive and robotic-assisted cancer surgery. The company's lead program, abenacianine for injection, is in Phase 2b clinical evaluation for lung cancer surgery applications.

2 investors

Verigraft develops personalized tissue-engineered products for severe diseases, including vascular grafts, nerve grafts, and heart valves, targeting regenerative medicine markets globally. The company's proprietary technology creates biological solutions for conditions such as chronic venous insufficiency, peripheral arterial disease, and heart valve disease.

2 investors

VerImmune develops immunotherapy medicines that redirect pre-existing immune memory toward cancer cells to achieve tumor destruction with low toxicity. The company targets cancer patients across a broad range of cancer types.

2 investors

Verinnogen develops data collection technology for pre-clinical cancer research, aiming to improve the accuracy, repeatability, and reliability of research data. The company draws on expertise in cancer biology and medical device development.

2 investors

Verinomics develops crop improvement technology by combining genomics, computational biology, and a transgene-free gene editing platform, with an AI-driven population genomics tool to identify high-value trait genes. It serves breeding programs, agricultural businesses, and research institutions focused on specialty and vegetatively propagated crops such as leafy greens.

2 investors

VERO Biotech develops next-generation inhaled nitric oxide (iNO) delivery systems for patients with cardiopulmonary conditions in acute care hospital settings. The company focuses on designing and commercializing innovative medical devices to address unmet clinical needs.

2 investors

Vertero develops therapies for neurodegenerative diseases by targeting causative mechanisms in the peripheral nervous system rather than addressing symptoms alone. The company uses discoveries in microbiology, pharmacology, and neuroscience to create novel drug treatments for patients with unmet needs.

2 investors

Vertosa develops water-dispersible emulsion technology and active ingredients that infused product makers, such as beverage and edibles producers, use to formulate stable, homogeneous, and bioavailable products. It provides customized aqueous solutions sold in bulk as dosed active ingredients along with formulation and manufacturing support.

2 investors

Vesalius Therapeutics develops a computational platform that identifies distinct disease subtypes within common diseases like heart failure, diabetes, and Alzheimer's by analyzing patient data and gene circuits, then uses proprietary cell-based models to discover targeted drug candidates. The company serves patients with prevalent chronic diseases using artificial intelligence, genomics, and patient-derived experimental models.

2 investors

VIA produces 3-Methylanisole (3-MA), a synthetic aromatic biofuel, through proprietary engineered yeast fermentation that converts starch, sugar, and cellulosic sugars into the aromatic compound. The company serves fuel manufacturers and chemical producers seeking scalable bio-based alternatives to petroleum-derived aromatics.

2 investors

ViaNautis develops targeted polyNaut nanovesicle (tPNV) delivery technology to advance cell and gene therapies and genetic medicines. A UCL spin-out originally established as SomaServe in 2018, the company operates from facilities in Cambridge, UK.

2 investors

Via Nova develops antiviral therapies targeting acute and subacute viral infections, including respiratory, gastrointestinal, and neurological infections. The company focuses on infections with high prevalence and severe illness potential, serving patients with unmet treatment needs across multiple viral categories.

2 investors

ViAqua Therapeutics develops RNA-based solutions to treat diseases in aquaculture, specifically targeting viral pathogens like White Spot Shrimp Virus in shrimp through oral feed application. The company serves aquaculture producers and works with animal nutrition and health sectors in Israel.

2 investors

Videra provides AI-powered technology that supports behavioral health clinicians by enhancing their capabilities and patient engagement to improve care delivery and outcomes. The platform serves behavioral health providers and healthcare systems, focusing on democratizing access to quality mental health care.

2 investors

ViewMind develops technology that provides objective, measurable data about brain function under cognitive stress to support clinical evaluation. The company's solution complements traditional biomarkers and imaging for healthcare providers.

2 investors

Nasdaq-listed clinical-stage immunology company in San Francisco developing hepatitis B/D antivirals and licensed T-cell engagers.

2 investors

Virion Therapeutics develops CD8+ T cell-based immunotherapies using genetically encoded checkpoint modifiers delivered with target-specific antigens via a viral vector platform, targeting cancers and chronic infectious diseases. Its lead product, VRON-0200, is in clinical development as a potential functional cure for chronic hepatitis B.

2 investors

ViroCarb is a biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its leadership brings experience in early-stage biopharma, medical devices, and industrial R&D.

2 investors

Vistim is a company leveraging neuroscience and artificial intelligence to develop solutions in the healthcare and medical technology space, drawing on expertise from neurology, brain-computer interfaces, EEG manufacturing, and pharmaceutical development.

2 investors

VisusNano develops ophthalmic drug delivery products, focusing on treatments for ocular and eye diseases. The company combines expertise in drug delivery, ophthalmic surgery, and clinical trials to create products for eye-care patients.

2 investors

Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.

2 investors

Vitranu develops biomaterial and biologic technologies for ophthalmic applications, particularly focused on retinal and vitreoretinal diseases. The company brings medical devices and therapeutics to market for eye care professionals and patients.

2 investors